🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Hemolytic Disease of the Fetus and Newborn (HDFN)

    phase 3 small molecule active

    1 trial

  2. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  3. Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo

    AstraZeneca AB

    Active Proliferative Lupus Nephritis

    phase 3 small molecule active

    1 trial

  4. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Blood and lymphatic diseases

    phase 3 small molecule active

    1 trial

  5. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Autoimmune haemolytic anaemia

    phase 3 small molecule active

    1 trial

  6. Sarilumab

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule completed

    1 trial

  7. Sarilumab SAR153191

    Regeneron UK Limited

    Corona Virus Infection

    phase 3 small molecule completed

    1 trial

  8. Sarilumab SAR153191

    Regeneron UK Limited

    Giant Cell Arteritis

    phase 3 small molecule terminated

    1 trial

  9. Sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Polymyalgia Rheumatica

    phase 3 small molecule terminated

    1 trial

  10. Sasanlimab

    Pfizer Australia Pty Ltd

    Non-Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  11. Satralizumab, Satralizumab

    Hoffmann-La Roche

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial

  12. Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  13. Selatogrel solution matching placebo, Selatogrel solution

    Viatris Pharmaceuticals Co.,

    Acute myocardial infarction (AMI)

    phase 3 small molecule active

    1 trial

  14. Semaglutide B 1.34 mg/mL PDS290 3.0 mL, Wegovy 2.4 mg solution for injection in pre-filled pen, Pre-filled syringe (glass) in a pre-filled pen: Semaglutide placebo Ia DV3396 pen-injector, 0.5 mL Semaglutide placebo Ib DV3396 pen-injector, 0.75 mL, Semaglutide B 0.68 mg/mL PDS290 1.5 mL, Semaglutide D 1.0 mg/mL DV3396, Semaglutide D 2.0 mg/mL DV3396, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Semaglutide B 3.2 mg/mL PDS290 3.0 mL

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  15. Sephience 250 mg oral powder in sachet, Sephience 1 000 mg oral powder in sachet

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  16. Sevoflurano Baxter 100% líquido para inhalación del vapor EFG, Propofol Fresenius 20 mg/ml emulsión inyectable y para perfusión EFG

    The George Institute

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  17. Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted), Cladribine Placebo, cladribine

    Merck Sharp and Dohme

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  18. Sildenafil placebo, Remidia, 20 mg, tabletki powlekane

    Cardiol Therapeutics

    Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.

    phase 3 small molecule active

    1 trial

  19. Simponi 50 mg solution for injection in pre-filled syringe., Simponi 45 mg/0.45 mL solution for injection in pre-filled pen., Simponi 100 mg solution for injection in pre-filled syringe.

    Janssen-Cilag Pty Ltd

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  20. Simvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 20 mg comprimidos recubiertos con película EFG, Simvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina Normon 60 mg comprimidos recubiertos con película, Simvastatina NORMON 20 mg comprimidos recubiertos con película EFG

    The George Institute

    Spontaneous lobar ICH

    phase 3 small molecule active

    1 trial

  21. Sinovac PCV13

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Diseases

    phase 3 mab active

    1 trial

  22. Sinovac PCV13

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 3 mab active

    2 trials

  23. Sipavibart, SODIUM CHLORIDE, EVUSHELD 150 mg + 150 mg solution for injection, EVUSHELD 150 mg + 150 mg solution for injection

    AstraZeneca AB

    COVID-19

    phase 3 small molecule active

    1 trial

  24. Skilarence 120 mg gastro-resistant tablets, MAGNESIUM STEARATE, MICROCRYSTALLINE CELLULOSE

    The George Institute

    Adrenomyeloneuropathy

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources